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Background: To examine the influence of ethnicity on liver transaminases among adolescents with type 2 diabetes
mellitus (T2DM).
Methods: A retrospective medical chart review of 57 (30 males and 27 females) newly diagnosed patients with
T2DM. Ethnicity was determined by self-report and height, weight, body mass index (BMI) and glycosylated
hemoglobin (HbA1c) were obtained using standard clinical procedures. Fasting levels of alanine aminotransaminase
(ALT) and aspartate aminotransferase (AST) were collected prior to the initiation of any therapy.
Results: Age, gender, height, weight, BMI, and HbA1c did not differ between ethnic groups. Compared to African-
Americans, Hispanics had significantly higher ALT (23.9 ± 3.4 vs. 107.8 ± 20.3, p=0.002) and AST (17.7 ± 2.5 vs. 71.1 ±
15.7, p<0.001) and were significantly more likely to have ALT values above the upper limit of normal (20% vs. 71%,
p=0.005) and twice the upper limit of normal (0% vs. 39%, p=0.05) as well as AST values above the upper limit of
normal (0% vs. 53%, p=0.002). No differences in ALT or AST were found between Hispanics and non-Hispanic whites or
between African-Americans and non-Hispanic whites.
Conclusions: These preliminary findings suggest that Hispanic children with T2DM may be at higher risk for
developing non-alcoholic fatty liver disease and indicate that a comprehensive hepatic evaluation is warranted in this
population. Future studies that incorporate more precise and proximal measures of liver health are warranted in this
population.
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Childhood obesity is increasing worldwide and nearly
35% of children and adolescents in the United States are
overweight or obese [1]. Coinciding with this epidemic is
an increase in obesity-related metabolic comorbidities
such as type 2 diabetes mellitus (T2DM) and non-
alcoholic fatty liver disease (NAFLD) [2,3]. These
chronic conditions present challenges to pediatric practi-
tioners as no consensus on their management exists and
there is limited evidence regarding long-term prognosis.
Both conditions appear to be related to the underlying
pathophysiologic process of insulin resistance [4,5] and
may act synergistically to place youth at increased risk* Correspondence: gabriel.shaibi@asu.edu
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reproduction in any medium, provided the orfor premature morbidity and mortality. Only 1 study to
date has examined NAFLD risk in youth with T2DM
and found that as many as 48% of those diagnosed with
T2DM also exhibit elevated liver transaminases [6]. The
authors concluded that the high prevalence of elevated
serum aminotransferases among children with T2DM
may be an indication of concomitant NAFLD in this
population.
Although pediatric obesity has increased worldwide,
certain ethnic subgroups of youth are disproportionately
impacted by both NAFLD and T2DM. In particular,
Hispanic and African-American adolescents are more
likely to present with T2DM compared to non-Hispanic
whites but Hispanic adolescents are thought to be at
highest risk for NAFLD while African-Americans are at
lowest risk [7]. To date, no studies have examined the
degree to which liver transaminases are differentially ele-
vated across ethnic groups among youth diagnosed withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hudson et al. BMC Pediatrics 2012, 12:174 Page 2 of 6
http://www.biomedcentral.com/1471-2431/12/174T2DM. Given the disproportionate burden of obesity-
related disease among minority youth, arriving at a bet-
ter understanding of NAFLD risk among youth with
T2DM is an important step for improving care and
management of this vulnerable population. Therefore,
the purpose of this preliminary study was to compare
serum liver transaminase levels as markers of NAFLD
risk in African-American, Hispanic, and non-Hispanic
white youth diagnosed with T2DM and assess whether
the degree to which these markers are elevated differs by
ethnicity.
Methods
Patients
The medical charts of patients seen with T2DM in the
Division of Pediatric Endocrinology at Phoenix Chil-
dren’s Hospital between 2005 and 2006 were reviewed.
The diagnosis of T2DM was based on the American
Diabetes Association criteria in those with negative islet
cell, GAD-65 and insulin antibodies [8]. Those diag-
nosed with T2DM based on known secondary complica-
tions of disease or medications (e.g., cystic fibrosis,
organ transplant anti-rejection treatment, chemother-
apy) or presumed liver disease secondary to viral ill-
nesses, genetic diseases of the hepatobiliary system or
autoimmune diseases were excluded. Also excluded were
patients in whom the method of diagnosis was not clear
or those with insufficient metabolic or ethnicity data
available. The Scientific Review Committee and Institu-
tional Review Boards of Phoenix Children’s Hospital
approved this study.
Data collection
The following was extracted from the medical charts:
age, gender, ethnicity, height, weight, BMI, HbA1C, and
fasting liver transaminases (ALT and AST). All labora-
tory values were determined at the time of diagnosis
prior to the initiation of therapy.
Data analysis
Data are reported as percentages for categorical variables
(gender, ethnicity) or means ± standard error for con-
tinuous variables (age, height, weight, body mass indexTable 1 Descriptive characteristics by ethnicity
Hispanic
Age at Diagnosis (yrs) 13.1 ± 0.3
Gender (M/F) 23/15
Height (cm) 161.7 ± 2.4
Weight (kg) 90.9 ± 11.0
BMI (kg/m2) 35.0 ± 1.1
HbA1C (%) 8.9 ± 0.9
Data expressed as means ± SEM. Abbreviations: BMI (body mass index).(BMI), ALT, AST, and HbA1c). General linear modeling
was used to compare metabolic variables between ethnic
groups with Bonferroni adjustments for multiple com-
parisons. Transaminases were log transformed for
normalization however un-transformed values are pre-
sented for ease of interpretation. Chi-Squared analyses
with Fisher exact test were performed to examine
whether the incidence of transaminases above the upper
limit of normal (ULN) (ALT ≥ 35 IU/L, AST ≥ 41 IU/L),
twice the ULN (ALT ≥ 70 IU/L, AST ≥ 82 IU/L) and
three times the ULN (ALT ≥ 105 IU/L, AST ≥ 123 IU/L)
differed by ethnicity based on normal values provided by
the clinical lab (Quest Diagnostics Inc, Nichols Institute,
San Clemente, CA). Statistical significance was deter-
mined based on a P value of < 0.05. SPSS statistics 18.0
was used to analyze the data (SPSS Inc, Chicago, IL).Results
Patients
Fifty-seven patients had pertinent metabolic and ethni-
city data available and were included in the present ana-
lysis. Descriptive characteristics are presented in Table 1.
Thirty-eight patients (66%) were identified as Hispanic,
10 (17%) were African-American and 9 (16%) were non-
Hispanic white. No significant ethnic differences were
noted in age, gender, height, weight, BMI, or HbA1C.Liver transaminase data
ALT and AST data are presented in Figure 1. Both ALT
and AST differed by ethnicity (R2 = 0.20, F = 6.768, p =
0.002 for ALT and R2 = 0.24, F = 8.804, p < 0.001 for
AST) with pair-wise comparisons showing Hispanic
youth with significantly higher ALT (p = 0.002) and AST
(P < 0.001) levels compared to African-Americans. No
significant differences were noted between Hispanics
and non-Hispanic whites for either ALT (p=1.0) or AST
(p=0.36). Similarly, no significant differences were noted
between non-Hispanic whites and African-Americans
for either ALT (p=0.09) or AST (p=0.18). Ethnicity
remained a significant predictor of both ALT and AST
after including BMI and HbA1c in the models (F=3.487,
p=0.04 and F=3.557, p=0.04, respectively).African-American Non-Hispanic White
13.8 ± 0.6 13.5 ± 01.1
1/9 6/3
160.7 ± 3.8 162.5 ± 5.7
92.6 ± 9.4 95.7 ± 11.0
38.9 ± 3.3 35.5 ± 3.5
9.6 ± 0.4 8.0 ± 0.9
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Figure 1 AB, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values in newly diagnosed youth with type 2
diabetes mellitus (T2DM). Data are presented as means ± SE.
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ULN, twice the ULN and three times the ULN by ethnicity
are presented in Table 2. Hispanics were significantly more
likely to have ALT levels above the ULN and twice the
ULN (p = 0.008 and 0.05, respectively) with a trend towards
significance for having ALT levels 3 times the ULN (p =
0.08) compared to African-Americans or non-Hispanic
whites. Additionally, Hispanics were more likely to have
AST levels above the ULN (p = 0.003) compared to other
groups.
Discussion
With the increased prevalence of childhood obesity noted
in recent decades, NALFD has become the most common
liver abnormality found among the pediatric population
[3]. Moreover, NAFLD risk is disproportionately higherTable 2 Percentage of patients with elevated liver transamina
Hispanic (%) African-Am
ALT - Normal 29 8
Above the ULN 71 2
Twice the ULN 39 0
Three times the ULN 29 0
AST - Normal 47 10
Above the ULN 53 0
Twice the ULN 21 0
Three times the ULN 8 0
ALT: Alanine aminotransferase, AST: aspartate aminotransferase, ULN: Upper Limit oamong Hispanic youth where elevated ALT levels have
been reported in more than 11% of Hispanic adolescents
in the US [9], almost 24% of overweight Hispanic youth
[10], and as many as 60% of obese Hispanic youth in a
clinical sample [11]. The current report extends the avail-
able science regarding NAFLD-related health disparities
to newly diagnosed adolescents with T2DM and suggest
that more than 70% of Hispanic youth with T2DM exhibit
elevated ALT levels. These data support recent findings
that youth with T2DM are at considerable risk for prema-
ture morbidity and mortality [12].
NAFLD and T2DM are thought to share a common
pathophysiology related to insulin resistance [13]. Obese
youth with NAFLD are significantly more insulin resist-
ant than obese youth who do not exhibit NAFLD [14].
Similarly, adolescents with T2DM are significantly moreses by ethnicity
erican (%) Non-Hispanic White (%) P-value
0 12
0 88 0.008
22 0.05
11 0.09
0 89
11 0.003
0 0.17
0 0.45
f Normal.
Hudson et al. BMC Pediatrics 2012, 12:174 Page 4 of 6
http://www.biomedcentral.com/1471-2431/12/174insulin resistant than BMI-matched adolescents with
normal glucose tolerance [4]. Although obesity and insu-
lin resistance are common characteristics of youth with
both NAFLD and T2DM, these traits alone do not ex-
plain why Hispanic patients in our study exhibited
higher transaminase values. Our patients exhibited simi-
lar descriptive and glycemic profiles in terms of obesity
and severity of diabetes (i.e. similar BMI and HbA1c)
which, suggests that ethnicity may further play a role
in the pathogenesis of NAFLD in the obese diabetic
population. Goran and colleagues [15] have reported
that Hispanic and African-American youth are significantly
more insulin resistant compared to non-Hispanic whites.
Interestingly, the authors noted that the associated
compensatory response to insulin resistance is different
between these minority groups and may indicate ethnic-
specific mechanisms underlying obesity-related diseases.
Unfortunately, glucose and insulin levels were not available
in our sample, limiting our ability to examine whether
variations in insulin resistance may contribute to the
observed differences in elevated transaminases between
groups. A study by Schwimmer et al [16] identified an
extremely high heritability estimate (h2 = 0.850; standard
error, 0.325), for fatty liver disease in a predominantly
Hispanic cohort suggesting that Hispanics may be pre-
disposed to developing NAFLD. This same group
hypothesized that African-Americans may either have a
protective factor or lack a vulnerability factor for the de-
velopment of fatty liver [17]. Collectively, these findings
suggest that genetic factors may contribute to the higher
risk of NAFLD among Hispanic youth. In particular,
when coupled with obesity, severe insulin resistance, and
T2DM, Hispanic youth may be at extreme risk for pre-
mature hepatic morbidity.
The retrospective nature of this report precludes
causal conclusions regarding ethnic-specific disease
mechanisms or trajectories. A recent study in a
community-sample of Korean adults suggests that eleva-
tions in ALT predict the development of T2DM over
time [18]. A study in obese youth from the United King-
dom suggests that youth with the metabolic syndrome
and those with a family history of T2DM, both of which
are risk factors for developing T2DM, are more likely to
exhibit elevated ALT levels [19]. Therefore, a prospective
study following normoglycemic youth as well as patients
with T2DM over time or through a course of treatment
may better identify potential causal relationships between
hepatic health and T2DM or whether gene-environment
interactions concomitantly impact the development
NAFLD and T2DM. Although our sample had fewer
African-Americans and non-Hispanic whites compared
to Hispanics this is most likely a function of the ethnic
disparities in T2DM risk coupled with the demographics
of the local Phoenix metropolitan area. Most of thepatients resided in Maricopa County Arizona where
Phoenix Children’s Hospital is the only tertiary care
referral center for Pediatrics. The most recent census
data (2010) showed Hispanics comprise 40.8% of the
population while African-Americans comprised 6.5%.
These data coupled with the demographics of the pa-
tient population in our study support disparities in
T2DM risk in the local community and may partially
explain the limited number of African-Americans
compared to Hispanics and non-Hispanic whites. We
acknowledge the limited sample size of the entire co-
hort and especially the non-Hispanic groups. To our
knowledge, the only other publication to date examin-
ing liver enzymes in youth with T2DM described 48
youth from Colorado in whom 65% (n=31) had liver
enzymes measured at diagnosis [6]. By comparison, the
multi-center SEARCH for Diabetes in Youth Study
representing 6-centers from four geographically defined
populations of 3.5 million youth identified a total of
446 African-American, Hispanic, and non-Hispanic
White youth with T2DM in their initial year [20].
Given the paucity of published data in youth with
T2DM and the fact that our report is the first to de-
scribe the impact of ethnicity on NAFLD in youth with
T2DM we expect that future studies will build upon
these findings using more representative samples.
It is noteworthy that elevated liver transaminases only
appear to be indicators of liver inflammation and are not
diagnostic of NAFLD [7]. However, in follow-up of six
Hispanic patients with ALT or AST more than twice the
ULN who underwent liver ultrasound, characteristics
consistent with fatty liver disease were found in all six.
Additionally, two of these patients had splenomegaly on
the ultrasound with follow up biopsy confirming fibrosis
(Grade III in a 15 y/o Hispanic male and Grade II in a
16 year old Hispanic female). The remaining four were
followed by both the endocrinology and gastroenterology
services. Future studies should employ more sophisti-
cated imaging methods such as magnetic resonance
spectroscopy to better quantify liver fat and NAFLD in
youth with T2DM [21]. Not only will these studies pro-
vide more definitive information on ethnic differences in
NAFLD risk, but may also be useful in developing clin-
ical prediction models for when and who to refer for
consult with a hepatologist.
As the prevalence of obesity increases in the pediatric
population it could be argued that all high-risk patients
including Hispanics and especially those newly diag-
nosed with T2DM have liver transaminases evaluated. In
support of this argument, the American Medical Associ-
ation recently released expert committee recommendations
regarding pediatric obesity which suggested biannual
screening for NAFLD by transaminase evaluation start-
ing at 10 years of age for children with a BMI ≥95th
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94th percentile who have other risk factors [22]. Further-
more, the committee suggested that ALT or AST results
2 times normal levels should prompt consultation with a
pediatric hepatologist. The importance of regular trans-
aminase evaluation is critical as hepatic inflammation
can quickly progress to frank fibrosis. In a review of chil-
dren diagnosed with NALFD in Toronto, Rashid et al
[23]. showed a high prevalence (77%) of progression to
liver inflammation and fibrosis. This rapid trajectory
underscores the importance of follow-up in those chil-
dren with elevated liver transaminases as end-stage com-
plications can be present in childhood. Particularly
concerning is the process starting at a young age even if
advanced findings are not yet present. Continued and
improved interaction between gastroenterologists and
pediatric endocrinologists are needed as the team ap-
proach to medical management of patients with T2DM
may require more comprehensive medical evaluation in-
cluding liver biopsies. At our institution, biopsies are typ-
ically performed only if the ultrasound suggests cirrhosis.
Further longitudinal studies may provide better guide-
lines regarding the progression of liver disease in relation
to the timing of biopsy. Our data also suggest that varia-
tions in the management should occur based on ethnici-
ties possibly using different timing of monitoring and
goals of treatment. One might more readily refer and/or
follow more closely a Hispanic patient with laboratory or
imaging studies suggesting NAFLD.Conclusions
Our preliminary findings suggest that Hispanic youth
with T2DM are more likely to have abnormal liver trans-
aminases, which, in turn, could indicate in a greater risk
for developing NAFLD compared to their African-
American and non-Hispanic white peers. Although these
findings need to be confirmed via prospective studies
using more accurate assessments of hepatic health, the
increasing rates of NAFLD and T2DM renders our re-
port important to clinicians and researchers working
with obese youth.
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